Therapeutic Area

Iron Deficiency Anemia

Therapeutic area intelligence for Iron Deficiency Anemia with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

Mylan →

Mylan Labs →

Assets

FDA →

Postpartum Depression →

Recent signals(3)

RegulatoryJuly 1, 2026

FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs

The FDA has approved the Abbreviated New Drug Application (ANDA) for Ferric Carboxymaltose submitted by Mylan Labs.

StrategyJuly 1, 2026

FDA Approves ANDA217769 for Ferric Carboxymaltose by Mylan

The FDA has granted approval for the Abbreviated New Drug Application ANDA217769 for Ferric Carboxymaltose submitted by Mylan.

ClinicalJune 25, 2026

IRON-DEP Study Evaluates IV vs Oral Iron for Postpartum Depression in Anemia

The IRON-DEP Study aims to compare the efficacy of intravenous and oral iron treatments on postpartum depression prevalence in women with moderate iron deficiency anemia post-caesarean.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Iron Deficiency Anemia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.